miR-210 is a Serological Biomarker for Predicting Recurrence and Prognosis of Colon Carcinoma Patients with Liver Metastases After Radiofrequency Ablation Treatment
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Colon Cancer | Colorectal Cancer | Hepatocellular Carcinoma | Liver | Liver Cancer | Urology & Nephrology